| Name | Title | Contact Details |
|---|
GlobalMedia Group, LLC is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Titan Instruments is a Hamburg, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Momentum Healthware Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At Fox Chase Cancer Center, defeating cancer is our calling. Fox Chase is one of the nation`s first dedicated cancer hospitals, and our researchers and physicians have made major contributions to scientific advancement since our establishment more than a century ago in 1904. Fox Chase scientists have made breakthroughs in cancer prevention, diagnosis, treatment, and survivorship, and have earned the highest awards in their fields, including two Nobel Prizes. We translate these pioneering discoveries into world-class clinical care every day - with a single purpose: to defeat cancer and help the people it impacts. This calling is rooted in our cancer-specific, multidisciplinary teams of doctors, researchers, practitioners, and five-time Magnet designated nurses, who are all more than specialists in cancer; they are international experts in distinct types of cancer, whose deep and focused expertise provides the best chance for the best outcome anywhere along the cancer continuum. And they`re helping to advance the way cancer treatment is delivered around the world. The way we work together, with this single, shared passion for our patients` well-being, is what makes us truly unique.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.